Rua Bioscience revenue surpasses forecast

Rua Bioscience has reported unaudited revenue of $693,829 for the six months ending Dec 31, 2024, surpassing the company's forecast of $600,000.

The strong performance was driven by higher-than-expected demand in key markets, particularly in Germany and New Zealand.

Rua's new dried flower products achieved exceptional sales in both countries, with Germany, as Europe's largest medicinal cannabis market, experiencing increased demand due to regulatory changes in April last year.

The company said its priorities for the remainder of the financial year include working with suppliers to increase volumes and expanding its product portfolio.